An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

AbbVie

Status and phase: Withdrawn; Phase 3

Conditions: Testosterone Deficiency; Hypogonadism

Treatments: Drug: ABT-SLV176

Study type: Interventional

Funder types: Industry

Identifiers

NCT02082197

M13-886

Details and patient eligibility

About

This is an open-study with a 26 week open label treatment period followed by an optional 26 week open label extension. The total treatment period will be 52 weeks.

Sex: Male

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Low testosterone

Exclusion criteria

• Normal testosterone levels
• Elevated Prostatic Specific Antigen (PSA)
• History of breast or prostate cancer

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

ABT-SLV176

Experimental group

Description:

ABT-SLV176 administered daily

Treatment:

Drug: ABT-SLV176